U.S. Consumer Finance Stock News

In recent days, analysts have reiterated positive views on Brookfield Infrastructure Partners while the company advanced plans to simplify its corporate structure into publicly traded corporations focused on renewable energy and infrastructure, aiming to preserve dividends and ease tax filing for investors. This combination of favorable analyst sentiment and a simplification that could boost liquidity and index inclusion is reshaping how investors evaluate Brookfield Infrastructure Partners...

With the Federal Reserve sending mixed signals on future rate cuts and hikes, inflation estimates edging higher, and oil prices reacting to conflict in Iran, many investors are taking a fresh look at large cap defensive dividend stocks. These companies, often in Consumer Staples, Utilities, and Healthcare, are commonly viewed as potential anchors when monetary policy and inflation expectations feel uncertain. This article focuses on how that backdrop connects to our US Large Cap Defensive...

Avnet stock has delivered a strong 145.2% return over the past 5 years, yet the company scores poorly on broader valuation checks, leaving investors weighing a solid track record against signals that the shares may not be a simple bargain at the current US$89.42 price. Over 5 years, Avnet has returned 145.2%, which puts recent gains into context as investors assess how much of the story is already reflected in the share price. Avnet's ability to convert its electronics distribution business...

Earlier this week, The Charles Schwab Corporation declared a regular quarterly cash dividend of US$0.32 per common share payable on August 28, 2026, alongside a series of preferred stock dividends scheduled for September 1, 2026. These dividend declarations, together with recently reported higher quarterly net income and earnings per share, highlight Schwab’s current emphasis on returning capital across both common and preferred shareholders. We’ll now examine how Schwab’s stronger quarterly...

Recent coverage of InvenTrust Properties (IVT) is centering on its pattern of annual dividend increases, a moderate payout ratio, and analyst expectations for earnings growth, all of which are drawing fresh attention from income-focused investors. See our latest analysis for InvenTrust Properties. At a share price of $36.45, InvenTrust Properties has posted a 12.12% 90 day share price return and a 30.74% year to date share price return. The 1 year total shareholder return of 36.62% and 3 year...

CME Group (NasdaqGS:CME) is rolling out 24/7 crypto trading and preparing new products such as Compute Futures for AI related exposure. The company is rejecting perpetual futures products and instead is putting emphasis on institutional risk management and retail access. Commentary around CME Group’s partnership with FanDuel points to growing friction over regulatory and credibility questions in sports related prediction markets. CME Group sits at the center of global derivatives trading,...

C3.ai (AI) is back in focus after a U.S. court dismissed in full a securities class action against the company, and recent results showed revenue and EPS ahead of consensus expectations. See our latest analysis for C3.ai. Despite the legal win and earnings beat, C3.ai’s recent share price return has been weak, with the stock at US$8.15 and down sharply on a year to date and multi year basis. This suggests enthusiasm has cooled even as investors reassess the company’s risk profile. If this...

Tenet Healthcare (THC) has reported another strong quarter, with Q2 2026 revenue of US$6.1 billion, basic EPS of US$9.89 and net income excluding extraordinary items of US$826 million setting the tone. The company’s quarterly revenue increased from US$5.3 billion in Q2 2025 to US$6.1 billion in Q2 2026, while basic EPS rose from US$3.16 to US$9.89 over the same period. Trailing 12 month earnings growth of 51% has coincided with a net profit margin that improved to 9.9% from 7.2% a year...

DocuSign (DOCU) jumped 5.6% on July 24, 2026, as part of a broad rally in software stocks. This move gave investors fresh reason to reassess how the stock fits into current sector trends. See our latest analysis for DocuSign. For context, DocuSign’s 14.01% 1 month share price return and 9.13% 3 month share price return contrast with a year to date share price decline of 22.22% and a 1 year total shareholder return decline of 36.85%. This points to short term momentum but a still weak longer...

Old Republic International (ORI) just reported mixed quarterly results, with stronger Title Insurance profitability offset by weaker Specialty Insurance performance. Technology and data investments, the ECM acquisition, and ongoing buybacks shaped how investors reacted. See our latest analysis for Old Republic International. Old Republic International’s mixed quarter and active buyback have come alongside a 1 day share price return of 2.35% and a 30 day share price return of 4.94%. The 1 year...

Investors are watching Fair Isaac (FICO) as attention builds around its upcoming July 29 earnings report, with the company’s shift toward SaaS and cloud-based delivery reshaping its revenue mix and margin profile. See our latest analysis for Fair Isaac. At a share price of $1,237.37, Fair Isaac has seen an 8.51% 1 month share price return and a 23.16% 3 month share price return. Its year to date share price has fallen 24.70%, and the 5 year total shareholder return of 136.18% points to...

Robotics and automation stocks sit at the crossroads of several forces investors are watching closely, from labor shortages and inflation pressures to shifting supply chains and energy uncertainty. As physical AI moves from pilot projects to wider deployment, some companies in the Robotics and Automation Stocks screener are aiming to turn that demand into revenue while keeping balance sheets under control. This article introduces the robotics theme in the context of central bank moves,...

Earlier this week, South Korean officials said Samsung Electronics secured a more than US$200.00 billion, five‑year contract to manufacture Broadcom chips on its advanced 2‑nanometer and smaller process technologies, reinforcing both companies’ push into AI infrastructure hardware through 2030. The scale and duration of this manufacturing deal give Broadcom greater access to cutting‑edge capacity outside Taiwan, potentially reshaping how it balances supply chain resilience with its ambitions...

In recent weeks, analysts have become more optimistic about Elastic’s earnings prospects, with upward revisions and a stronger consensus that the company may outperform prior profit expectations. This rising optimism around earnings quality and trajectory has become a key influence on how investors interpret Elastic’s role in the AI-powered data and search software space. We’ll now examine how this shift in analyst earnings expectations reshapes Elastic’s existing investment narrative built...

Global trade tensions are heating up again, with fresh US tariffs of 10% to 12.5% on imports from more than 60 countries and a swift response from China adding to supply chain uncertainty. For logistics and freight providers, this mix of higher costs, rerouted trade flows, and shifting customer demand can create both pressure and opportunity. This article discusses 3 stocks from our Global Logistics and Freight Providers screener that are directly exposed to the latest tariff moves and...

Volkswagen engineers have been charged with insider trading linked to the planned joint venture with Rivian Automotive, raising fresh legal and governance questions around NasdaqGS:RIVN and its largest shareholder. Rivian has filed a lawsuit against the US government seeking a refund of Trump-era tariffs, arguing the duties are unconstitutional and have inflated its input costs. These developments add new legal, regulatory, and reputational angles to the Rivian story beyond earlier debates...

HCA Healthcare has reported past Q2 2026 results with revenue rising to US$20.23 billion and net income to US$1.70 billion, alongside EPS of US$7.62 and a completed buyback of about 2.86% of shares for roughly US$2.88 billion. Beneath the headline growth, management highlighted a payer mix shift toward more uninsured patients that reduced pre-tax income by about US$400 million, prompting a trimmed full-year profit outlook despite solid demand and ongoing capital investment. Next, we will...

Recently, analysts highlighted that Reinsurance Group of America is facing growth constraints versus smaller peers, with earnings per share lagging revenue gains and book value per share projected to fall over the next year amid softer capital generation. This commentary raises questions about the strength of RGA’s internal capital engine at a time when it remains a major life and health reinsurer globally. We’ll now examine how concerns over weakening capital generation and book value...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Fastenal Company ( NASDAQ:FAST ) stock is about to trade ex-dividend in two days. The ex-dividend date is one business...

Molson Coors Beverage (TAP) is back in focus after fresh analysis highlighted its record of outperforming earnings estimates, with a large positive surprise in the latest quarter contributing to current upbeat expectations. See our latest analysis for Molson Coors Beverage. Alongside the upbeat earnings narrative, Molson Coors Beverage’s recent share price has been more subdued. The stock closed at $40.95 with a 1-day share price return of 2.27%, but its year-to-date share price return is...

Twenty One Capital (XXI) is back in focus after CEO Jack Mallers resigned on July 20, 2026, and board member Raphael Zagury stepped in as chief executive on the same date. See our latest analysis for Twenty One Capital. The CEO transition at Twenty One Capital comes after a sharp reset in investor expectations, with the share price down 42.05% over the past 90 days and the year to date share price return declining 51.40%. The 1 year total shareholder return has fallen 83.97%, pointing to...

Why Axsome Therapeutics Stock Is Back in Focus After the Latest FDA Milestone Axsome Therapeutics (AXSM) is drawing fresh attention after the U.S. Food and Drug Administration accepted its New Drug Application for AXS-12, an investigational treatment for cataplexy in narcolepsy, and set a PDUFA target action date of May 1, 2027. See our latest analysis for Axsome Therapeutics. For investors, the FDA’s acceptance of AXS-12 comes as Axsome Therapeutics’ share price has risen 29.6% over the past...

Columbia Sportswear stock has been weak over the past few years, yet the latest Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside compared with where the shares currently trade. At the same time, broader valuation checks suggest a mixed picture rather than a clear bargain or clear overvaluation. Over the past 5 years, Columbia Sportswear shares have declined about 32%, which puts recent returns out of step with the current DCF indication of undervaluation. For...